Guo Xing, Chen Teng, Chen Shiming, Song Chao, Shan Dezhi, Xu Shujun, Xu Shuo
Department of Neurosurgery, Qilu Hospital, Cheeloo College of Medicine and Institute of Brain and Brain-Inspired Science, Shandong University, Jinan, China.
Shandong Key Laboratory of Brain Function Remodeling, Jinan, China.
Front Oncol. 2021 Dec 16;11:739309. doi: 10.3389/fonc.2021.739309. eCollection 2021.
As an oncogenic somatic variant, telomerase reverse transcriptase promoter (TERTp) mutations are frequently observed in adult glioblastoma (GBM). Alternatively, we report the first case of glioblastoma with TERT amplification accompanied by multiple TERT and FGFR2 gene fusions instead of TERTp mutation. A 55-year-old woman presented with dizziness, headache, and diplopia for three weeks. Magnetic resonance imaging (MRI) demonstrated a heterogeneously enhancing lobulated mass centered in the pineal region. Partial tumor resection and ventriculoperitoneal shunt were achieved, and the residual tumor was then treated with standard radiation. The tumor was diagnosed as GBM, IDH-wild type, WHO grade IV, and the Ki67 proliferation index was high (30-40%). Intriguingly, TERT amplification without TERTp mutation was identified next generation sequencing (NGS). Further analysis revealed multiple TERT (TERT-NUBPL, MARCH6-TERT, and CJD4-TERT) and FGFR2 (CXCL17-FGFR2, SIPA1L3-FGFR2, FGFR2-SIPA1L3, and FGFR2-CEACAM1) gene fusions. After the surgery, the patient's condition deteriorated rapidly due to the malignant nature of the tumor and she died with an overall survival of 3 months. Our report provides the molecular clue for a novel telomerase activation and maintenance mechanism in GBM.
作为一种致癌体细胞变异,端粒酶逆转录酶启动子(TERTp)突变在成人胶质母细胞瘤(GBM)中经常被观察到。另外,我们报告了首例伴有TERT扩增并伴有多个TERT和FGFR2基因融合而非TERTp突变的胶质母细胞瘤病例。一名55岁女性出现头晕、头痛和复视三周。磁共振成像(MRI)显示松果体区有一个中心为分叶状、不均匀强化的肿块。进行了部分肿瘤切除和脑室腹腔分流术,然后对残留肿瘤进行了标准放疗。该肿瘤被诊断为GBM,异柠檬酸脱氢酶(IDH)野生型,世界卫生组织(WHO)IV级,且Ki67增殖指数较高(30 - 40%)。有趣的是,通过下一代测序(NGS)鉴定出TERT扩增但无TERTp突变。进一步分析发现多个TERT(TERT - NUBPL、MARCH6 - TERT和CJD4 - TERT)和FGFR2(CXCL17 - FGFR2、SIPA1L3 - FGFR2、FGFR2 - SIPA1L3和FGFR2 - CEACAM1)基因融合。手术后,由于肿瘤的恶性性质,患者病情迅速恶化,最终死亡,总生存期为3个月。我们的报告为GBM中一种新的端粒酶激活和维持机制提供了分子线索。